Cornea and External Disease

Positive trial results announced for TTHX1114 in patients with fuchs endothelial corneal dystrophy

Trefoil Therapeutics recently announced positive Phase 2 results for TTHX1114, an engineered fibroblast growth factor-1 (FGF1) variant, in patients with fuchs endothelial corneal dystrophy (FECD). TTHX1114 is delivered as an intracameral injection into the anterior chamber of the eye of patients undergoing a Descemet Stripping Only (DSO) procedure. After a...